Brookfield Infrastructure 주식 (NYSE: BIPC)

에 대한 최신 뉴스 Brookfield Infrastructure (NYSE:BIPC) 주식

Brookfield Infrastructure

Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.

Ordinary Shares - Class A (Exchangeable Sub Voting)

Brookfield Infrastructure Corporation Brookfield Infrastructure Corporation

Brookfield Infrastructure Corp

Partners With ASE to Scale AI Nose Deployment and Set New Standard in Intelligent Sensing
Achieves Strategic Inflection Point in 1H 2025 with Partnerships and Operational Breakthroughs
SAN DIEGO, CALIFORNIA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / Ainos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMDW#NASDAQ">AIMDW</a>) ("Ainos" or the "Company") today announced the completion of a 1-for-5 stock consolidation, effective at the opening of trading on June 30, 2025. The move strengthens the Company's capital structure, aligns with Nasdaq listing requirements, and positions Ainos to scale global commercial operations across its AI Nose platforms.

News

AIMD

AIMDW

Ainos Completes 1-For-5 Stock Consolidation; Partners With ASE To Scale AI Nose Deployment

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP&#xAE;) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP&#xAE; companion diagnostic specific to stenoparib.
The acceptance covers 40 claims and marks a key step in Allarity's global strategy to protect the potential international commercialization of its proprietary DRP&#xAE; platform alongside the clinical development of stenoparib. The granted patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted within 20 working days thereafter.

Biotech

Global

General

ALLR

Allarity Therapeutics' Patent Application For DRP Companion Diagnostic For Stenoparib Accepted By IP Australia

JOBY

Joby Completes Series Of Flights In dubai

Regulated entities can streamline stablecoin operations - permissioned or permissionless - using ALT5 Sigma's Crypto-as-a-Service platform, fully compatible with proprietary and third-party assets.
LAS VEGAS, NV / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / ALT5 Sigma Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>)(FRA:5AR1), a leading provider of Crypto-as-a-Service infrastructure, has launched a comprehensive stablecoin management solution for U.S. institutions. Designed for regulated entities, the platform enables seamless integration, utilization, and oversight of stablecoins-regardless of the issuing entity or blockchain protocol. Whether managing proprietary tokens or leveraging market leaders, institutions can operationalize, monitor, and scale stablecoin use through ALT5 Sigma's infrastructure. Integration with existing workflows and systems is supported via robust APIs.

ALTS

ALT5 Sigma Launches Stablecoin Management Platform For U.S. Institutions, Enabling Seamless Integration Across Blockchains And Issuers

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) and Accenture Federal Services, a unit of Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>), have formed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46164859/palantir-and-accenture-federal-services-join-forces-to-help-federal-government-agencies-reinvent-o/" rel="noreferrer noopener">strategic partnership</a> to provide cutting-edge artificial intelligence capabilities to U.S. federal agencies.
Under the agreement, Accenture Federal becomes a preferred implementation partner for Palantir&#8217;s platforms, focusing on enhancing mission-critical workflows and strengthening government operations through AI.
The collaboration will initially roll out three specialized offerings: &#8220;Enterprise-to-Edge Data Fusion,&#8221; which modernizes legacy systems to deliver real-time data to frontline operations; &#8220;Predictive Supply Chain Orchestration,&#8221; a tool to optimize and automate logistics across agencies; and &#8220;Operationalizing Financial Intelligence,&#8221; a solution designed to improve fiscal oversight by integrating budget data across systems.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46059174/accentures-raised-outlook-fails-to-ease-fiscal-2026-softness-worries-analyst" rel="noreferrer noopener">Accenture&#8217;s Raised Outlook Fails To Ease Fiscal 2026 Softness Worries: Analyst</a>
Accenture Federal will train and certify 1,000 members of its Data &amp; AI team on Palantir&#8217;s Foundry and AI Platform to support these efforts, building a delivery force capable of executing scalable, AI-enabled solutions across government functions.
Dr. Alex Karp, Palantir&#8217;s CEO, described Accenture as a &#8220;natural partner,&#8221; noting both firms share a commitment to delivering measurable impact. Julie Sweet, Chair and CEO of Accenture, emphasized how the partnership combines commercial innovation with federal expertise to modernize public services.
Mike Galagher, Palantir&#8217;s defense lead, framed the initiative as essential to national security, enabling smarter decisions on the battlefield.
Ron Ash, CEO of Accenture Federal Services, called the partnership a transformational step for government agencies seeking faster, more informed decision-making. &#8220;This is a game changer for our federal customers,&#8221; he said, pointing to the value of embedding AI into everyday agency operations.
Related ETFs: Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>), iShares U.S. Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>).
Price Action: ACN shares gained 1.15% at $298.85, and PLTR was up 4.76% at $136.96 premarket on Monday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46161429/canada-rescinds-digital-services-tax-after-trump-calls-it-a-blatant-attack-on-america" target="_blank" rel="noreferrer noopener">Canada Rescinds Digital Services Tax After Trump Calls It A &#8216;Blatant Attack&#8217; On America</a></li>
</ul>
Image via Shutterstock

Movers

Tech

iShares Dow Jones US Technology Sector Index Fund

PLTR

Palantir, Accenture Partner To Infuse AI Into Federal Agency Workflows

IMNN

IMUNON Submits Plan To Nasdaq To Regain Compliance with Minimum Bid Price Requirement

Agreement with Beijing Tongchuang Technology Development Co., Ltd. strengthens regional momentum through purchase, service, and licensing of flagship products
LAS VEGAS, June 30, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=tW_2zKoMPl4BWuM8L1BcEyj_jlqmqVW1MpAdGRQAlmZLUDV9b1egs8l78NifrUwOeWL6-u1mz_WBbHXQJIcZCuLer6wbhqv2UefGj1nva38=">Richtech Robotics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) ("Richtech Robotics" or the "Company"), a Nevada-based provider of AI-driven service robots, today announced the signing of a multi-million-dollar sales agreement with Beijing Tongchuang Technology Development Co., Ltd. by its Chinese joint venture, Boyu Artificial Intelligence Technology Co., Ltd.
The agreement, valued at over $4 million, includes the purchase, service, and software licensing of products from three of Richtech's key product lines: ADAM, Scorpion, and Titan. The deal expands the company's footprint in China and opens the door for additional potential opportunities across the Asian market. The agreement is expected to increase the company's fourth quarter revenue as well as to drive recurring revenue moving forward.

Contracts

Richtech Robotics Signs $4M Sales And Licensing Agreement In China To Expand Presence And Boost Q4 Revenue Through Flagship AI Robot Products

CDTX

Cidara Therapeutics Announces Addition To Russell 2000 And Russell 3000 Indexes

Eve Air Mobility ("Eve") (NYSE:<a href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>, EVEXW))&nbsp;has signed a Letter of Intent (LOI) with Aerosolutions, which is developing an innovative eVTOL operator called Aeros Electric Airlines, and Bluenest by Globalvia, Globalvia's Advanced Air Mobility infrastructure developer and vertiport operator, for the sale of up to 50 electric vertical take-off and landing (eVTOL) aircraft and access to Eve's comprehensive TechCare services—an all-in-one portfolio of services designed to streamline eVTOL operations, maintenance, and customer support. The agreement marks a significant step toward developing a robust Advanced Air Mobility (AAM) ecosystem in Costa Rica.

EVEX

Eve Air Mobility Signs LOI With Aerosolutions, And Bluenest By Globalvia For Sale Of Up To 50 eVTOL Aircraft And Access To Eve's Comprehensive TechCare Services

High-performance wireless solution delivers low-latency video without burdening school networks, demonstrating benefits of 60 GHz solutions in congested Wi-Fi environments
SAN JOSE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / <a href="https://pr.report/bwvp">Peraso Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) ("Peraso" or the "Company"), a pioneer in mmWave wireless technology solutions, today announced its first production order for a wireless video system specifically tailored for educational environments. The new order marks an expansion of Peraso's technology into the classroom, delivering a high-performance, low-latency solution that operates independently of existing school Wi-Fi infrastructure.
Unlike traditional Wi-Fi, which often struggles in high-density deployments, Peraso's 60 GHz solution reduces interference by isolating wireless transmissions to individual classrooms. The Company's latest deployment underscores a growing trend: as Wi-Fi networks in dense environments become increasingly congested, 60 GHz unlicensed spectrum is emerging as an alternative for reliable, high-speed wireless connectivity. Peraso's mmWave solutions are engineered to excel in bandwidth-constrained settings, offering reduced interference and improved performance for applications such as classroom video distribution and live instructional streaming.

PRSO

Peraso Secures Its First Production Order For A Wireless Video System Specifically Tailored For Educational Environments

TARA

Protara Therapeutics Announces Addition To Russell 3000 Index

Digital asset investment products attracted $2.7 billion in inflows last week, extending their positive streak to 11 consecutive weeks and bringing first-half <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45957567/bitcoin-ethereum-lead-1-9-billion-digital-asset-inflows-amid-global-tensions-coinshares-finds">inflows to $17.8 billion</a>, according to CoinShares&#8216; fund flows report on Monday. 
This figure is nearly in line with the $18.3 billion recorded in the same period in 2024, pointing toward a steady investor demand despite heightened global uncertainty.
CoinShares analysts <a href="https://blog.coinshares.com/volume-240-digital-asset-fund-flows-weekly-report-35a6ac1da67c">noted</a> that geopolitical volatility and questions over the direction of monetary policy were key drivers behind the sustained inflows.
The report highlighted that the majority of the capital came from the U.S., which accounted for $2.65 billion of last week's total. 
Meanwhile, Switzerland and Germany posted modest inflows of $23 million and $19.8 million, respectively.
In contrast, Hong Kong recorded persistent outflows, totaling $132 million for June. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46165366/circle-stock-is-a-must-hold-says-bernstein-heres-why">Circle Stock Is A &#8216;Must Hold,&#8217; Says Bernstein: Here&#8217;s Why</a>
CoinShares linked this trend to recent crypto price volatility in the region. Minor outflows were also observed in Canada and Brazil.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dominated activity, accounting for 83% of inflows last week, or $2.2 billion. 
Short Bitcoin products continued to see outflows, with $2.9 million withdrawn last week, signaling investor optimism toward Bitcoin's price outlook.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) investment products attracted $429 million in inflows last week, bringing the year-to-date total to $2.9 billion.
In contrast, Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) saw more subdued demand, with just $91 million in inflows year-to-date.
The report emphasized that despite market volatility and shifting regional participation, investors remain broadly supportive of major digital assets, particularly Bitcoin and Ethereum.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46148904/donald-trump-says-bitcoin-takes-a-lot-of-pressure-off-the-dollar">Donald Trump Says &#8216;Bitcoin Takes A Lot Of Pressure Off The Dollar&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

Bitcoin ETFs Extend Record $2.2B Net Inflows To Extend Streak To 11 Weeks

Garrett Motion Added To Russell 2000 Index

Logistic Properties Of The Americas Joins Russell 3000 And Russell Microcap Indexes

NextPlat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>, NXPLW)), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter:
To Our Shareholders:
As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward.
In the month since the unexpected passing of our former CEO and Chairman, Charles M. Fernandez, our team has been closely reviewing our operations to build on the strong foundation he helped create. As part of this, I personally met with leaders across our subsidiaries and was truly impressed by the passion and dedication of our highly experienced employees. Based on the insights I gathered, I'm confident that with greater focus, improved coordination, and targeted investment, NextPlat is well-positioned to capitalize on the opportunities ahead and unlock significant value.
Where We Are Today
Having completed my initial review, I believe that our healthcare division is particularly critical to our future success as it currently represents the largest part of our business and offers significant untapped opportunities to explore. I believe there are several areas that we need to address if we are to properly support the business and reach our long-term goals, foremost amongst them being:
<ul>
<li>Continued operational process efficiency and cost reduction efforts to drive maximum&nbsp;ROI</li>
<li>Ensuring that we have the necessary talent leading our units and that they are empowered to manage and drive growth</li>
<li>Renewing a commitment to prudently invest in the business to help capitalize on growth opportunities, both organic and non-organic, while enhancing&nbsp;cashflow and long-term profitability</li>
</ul>
Where We Are Going – Pharmacy and Healthcare
As we've previously communicated, the retail pharmacy sector continues to face unprecedented challenges driven by rising drug costs and made worse by reimbursement rates not keeping pace with those rising costs. Therefore, our focus must remain on executing the business of the Company efficiently and investing in alternative areas of healthcare that offer growth potential.
To that end, we've been working to streamline our current healthcare operations and expand our contracted 340B and long-term care (LTC) services, both of which present opportunities for profitable growth. We also intend to take several strategic steps within our healthcare business, including:
<ul>
<li>Adding experienced healthcare leadership to the team to drive growth and enhance the daily management and profitability of the business</li>
<li>Expanding into new, high growth/high margin healthcare services through joint ventures and partnerships</li>
<li>Implementing a number of process and technology improvements designed to drive additional operational efficiencies, improve compliance, and attract a new customer demographic</li>
<li>Make further investments into marketing and sales programs targeting 340B and&nbsp;LTC providers, including the exploration of obtaining licenses in nearby southeastern states where additional 340B opportunities exist</li>
<li>Adding complementary services such as compounding, additional OTC products, and exploring opportunities such as opening in-house pharmacies</li>
<li>Pursuing special accreditation to enable us to dispense specialty medications, potentially leading to broader patient access and increased prescription volume on high margin sales</li>
<li>Begin targeting the non-insured (cash) sales market to diversify revenue streams and reduce dependence on insurance reimbursements</li>
<li>Evaluate opportunities for nationwide licensing to enable&nbsp;e-Commerce mail-order sales</li>
<li>Improving customer service responsiveness, access and support</li>
</ul>
Where We Are Going - E-Commerce
Although e-Commerce represents a smaller part of NextPlat's overall business, I have spoken in the past about the vast global opportunity and potential we see in this business. Through leading e-Commerce marketplaces such as Amazon.com, Walmart, and Alibaba in China, as well as our own network of branded online storefronts, we have created a global presence supporting tens of thousands of customers in over 150 countries. This is something we intend to build on.
Recently, new tariffs, particularly between the U.S. and China, have delayed product launches like our Florida Sunshine vitamin brand, but we still see strong global opportunities ahead. That is why we are focusing on growing our e-Commerce business through a series of initiatives including:
<ul>
<li>Further scaling our global&nbsp;e-Commerce presence through small, opportunistic acquisitions that bring accretive sales, distribution and potentially, valuable contracts and customer lists</li>
<li>Launching new international marketplaces, forming new distribution partnerships, and introducing new products and services to further expand our global customer base</li>
<li>Advance our recently launched storefront design and product management service for hardware manufacturers and connectivity services providers, helping them to build, optimize, and grow their brands in the world's largest online marketplaces and reach new customers.</li>
<li>Expanding our&nbsp;e-Commerce partnership with OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) ("OPKO") for sales into China of its health, nutrition, and dietary supplement products, adding unique animal care products later this year, all of which are not subject to any current tariffs</li>
<li>Continuing to explore opportunities to launch our Florida Sunshine vitamin brand in the UK and&nbsp;EU, following a setback of this project as a result of Chinese tariffs.</li>
</ul>
For Our Shareholders
As I indicated earlier in this update, the team at NextPlat shares a common belief in the long-term opportunities ahead of us and the ability to build upon the strong foundation created under Charlie's leadership. Our internal business review identified our strengths as well as areas that need immediate attention and improvement if we are to meet our growth and profitability objectives. That is why we are committed to addressing several areas and needs in the business, including:
<ul>
<li>Accelerating ongoing efforts to maximize efficiencies across the organization with the bottom-line goal of generating positive operating results and&nbsp;ROI</li>
<li>Investing in our operations and our people to profitably expand and grow the business</li>
<li>Fill gaps in our team and empower our leaders to execute against their respective growth plans</li>
<li>Implement the stock buyback program previously announced</li>
<li>Continue to improve shareholder transparency and engagement including outreach to the broader investor community</li>
</ul>
A Thank You
In conclusion, we must thank our partners, customers, employees, and investors for their continued support and wish to confirm our pledge that we&nbsp;intend to use recent developments as a catalyst for change and as an opportunity to advance Charlie's legacy. Although we have challenges ahead, Charlie created a strong and well-funded foundation for us to build on, and both I and our Board are committed to realizing and surpassing the potential he saw for NextPlat in the months and years ahead.
Sincerely,
David Phipps Interim Chief Executive Officer

NXPL

NextPlat Interim CEO  Issues Shareholder Letter Outlining Strategic Vision For Growth In Healthcare And E-Commerce

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), a clinical-stage company focused on oncology and obesity, today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety and pharmacokinetics (PK) data analysis of the single ascending dose (SAD) study launched in March. The MAD portion of this clinical study is scheduled for completion in the third quarter of this year.
The MAD portion of the Phase 1 trial is designed to test a once-daily dosing of CRB-913 for 7 days. Similarly to the SAD study, the MAD study is undertaken with healthy volunteers and focuses on safety, tolerability and PK of increasing doses of CRB-913. The study is being conducted in the United States.
The SAD/MAD portion of the Phase 1 trial is scheduled to be completed in Q3 of 2025, and the Company expects to commence a Phase 1b dose-range finding study in Q4 of 2025. The dose-range finding study is scheduled for completion in the second half of 2026.

CRBP

Corbus Pharma Initiates Multiple Ascending Dose Portion Of Phase 1 Trial For CRB-913, Peripherally Restricted CB1 Inverse Agonist For Obesity Treatment; MAD Study On Track For Completion In Q3 2025

<h3>Gainers</h3>
<ul>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock increased by 13.7% to $1.12 during Monday's pre-market session. The company's market cap stands at $70.4 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock increased by 10.45% to $0.78. The company's market cap stands at $76.4 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock increased by 9.9% to $1.22. The market value of their outstanding shares is at $18.1 million. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) stock moved upwards by 9.71% to $0.78. The company's market cap stands at $21.9 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 9.38% to $0.99. The company's market cap stands at $17.3 million. </li>
<li>Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) stock moved upwards by 8.33% to $4.03. The market value of their outstanding shares is at $157.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) shares declined by 39.7% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $8.1 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 5.67% to $1.25. The company's market cap stands at $4.2 million. </li>
<li>Dogness (Intl) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) stock decreased by 5.23% to $27.05. The market value of their outstanding shares is at $406.1 million. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) shares declined by 5.1% to $8.92. The market value of their outstanding shares is at $16.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENN

CTNT

DOGZ

GDHG

PRPL

TKLF

YOSH

10 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) stock moved upwards by 165.2% to $18.01 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares rose 41.64% to $1.02. The company's market cap stands at $26.2 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock rose 25.68% to $2.74. The market value of their outstanding shares is at $4.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares increased by 22.68% to $1.99. The market value of their outstanding shares is at $120.4 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock moved upwards by 22.04% to $11.57. The market value of their outstanding shares is at $246.6 million. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares rose 14.48% to $1.66. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares fell 57.4% to $2.27 during Monday's pre-market session. The market value of their outstanding shares is at $124.6 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares fell 31.06% to $2.82. The market value of their outstanding shares is at $154.0 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 20.4% to $1.6. The market value of their outstanding shares is at $5.5 million. </li>
<li>Odysight ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODYS#NASDAQ">ODYS</a>) shares decreased by 20.12% to $5.6. The market value of their outstanding shares is at $114.3 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock declined by 16.92% to $5.65. The company's market cap stands at $82.0 million. </li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) shares decreased by 16.08% to $2.35. The market value of their outstanding shares is at $18.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ARTL

INMB

KLTO

LIMN

MEIP

ODYS

QTTB

SERA

UNCY

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares increased by 128.6% to $4.0 during Monday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) stock moved upwards by 38.29% to $1.95. The market value of their outstanding shares is at $8.8 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) shares increased by 22.82% to $2.95. The market value of their outstanding shares is at $36.6 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock rose 16.39% to $0.15. The market value of their outstanding shares is at $1.9 million. </li>
<li>Tecogen (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGEN#AMEX">TGEN</a>) stock rose 15.84% to $8.28. The company's market cap stands at $180.6 million. </li>
<li>Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) stock rose 13.84% to $25.25. The company's market cap stands at $5.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>JVSPAC Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) shares fell 52.4% to $5.09 during Monday's pre-market session. The market value of their outstanding shares is at $82.2 million. </li>
<li>Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares decreased by 24.59% to $54.0. The market value of their outstanding shares is at $24.3 billion. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares decreased by 13.89% to $13.96. </li>
<li>Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares fell 13.32% to $4.1. The company's market cap stands at $790.7 million. </li>
<li>Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) shares decreased by 9.9% to $52.55. The market value of their outstanding shares is at $8.7 billion. </li>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) shares fell 6.33% to $1.63. The company's market cap stands at $11.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWNB

IPDN

JVSA

LASE

MNTS

SHLS

SYNX

TGEN

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares rose 41.1% to $6.02 during Monday's pre-market session. The company's market cap stands at $25.8 million. </li>
<li>Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) stock increased by 14.06% to $21.0. The company's market cap stands at $24.1 billion. </li>
<li>3 E Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASK#NASDAQ">MASK</a>) shares increased by 12.56% to $2.5. The company's market cap stands at $24.9 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 11.03% to $0.84. The company's market cap stands at $40.6 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) shares rose 9.09% to $1.08. The company's market cap stands at $11.8 million. </li>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock moved upwards by 8.9% to $1.59. The company's market cap stands at $52.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares declined by 44.7% to $0.2 during Monday's pre-market session. The market value of their outstanding shares is at $23.1 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares declined by 19.4% to $6.69. The market value of their outstanding shares is at $10.5 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock decreased by 14.43% to $2.73. The company's market cap stands at $1.4 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock fell 14.19% to $0.3. The company's market cap stands at $37.5 million. </li>
<li>ChipMOS TECHNOLOGIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMOS#NASDAQ">IMOS</a>) stock fell 10.92% to $16.49. The market value of their outstanding shares is at $663.8 million. </li>
<li>Interlink Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINK#NASDAQ">LINK</a>) stock decreased by 9.61% to $6.4. The market value of their outstanding shares is at $69.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

BMNR

IMOS

LCFY

LINK

MASK

MOBX

SVRE

WETH

XTKG

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Press Releases

Brookfield Infrastructure to Host Second Quarter 2024 Results Conference Call

Brookfield Infrastructure Announces Reorganization of Brookfield Infrastructure Corporation

Brookfield Infrastructure Announces Closing Date of Reorganization

Brookfield Infrastructure Corporation Announces Results of Annual Meeting of Shareholders

Comments

Brookfield Infrastructure

뉴스

에 대한 최신 뉴스 Brookfield Infrastructure (NYSE:BIPC) 주식

뉴스

파트너 / 기고자

벤징가 글로벌